We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Dose-dense (Biweekly) Carboplatin Plus Paclitaxel With or Without Trastuzumab as Neoadjuvant Treatment for Breast Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02059876
Recruitment Status : Unknown
Verified November 2013 by Guangdong General Hospital.
Recruitment status was:  Recruiting
First Posted : February 11, 2014
Last Update Posted : February 12, 2014
Information provided by (Responsible Party):
Guangdong General Hospital

Results Submitted - Not Posted on ClinicalTrials.gov
Results information has been submitted to ClinicalTrials.gov by the sponsor or investigator, but is not yet publicly available (or "posted") on ClinicalTrials.gov. The submitted information may not be available if it is pending Quality Control (QC) Review by the National Library of Medicine (NLM) or if issues identified during QC review are being addressed or corrected by the sponsor or investigator. NLM's limited QC review assesses for apparent errors, deficiencies, or inconsistencies. NLM staff do not verify the scientific validity or relevance of the submitted information.
  Recruitment Status : Unknown
  Estimated Primary Completion Date : December 2014
  Estimated Study Completion Date : December 2014

Submission Cycle Results Submitted to ClinicalTrials.gov Results Returned after Quality Control Review
1 February 24, 2017 April 7, 2017
2 October 25, 2017